Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viloxazine Excretion in Breast Milk
NCT06259331Phase 4Completed
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Start
- May 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of viloxazine in attention deficit hyperactivity disorder (ADHD), sponsored by Supernus Pharmaceuticals, Inc.. Started May 2023; status: completed.
02
Drugs
viloxazine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT06259331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06259331.